Biology of the blood-nerve barrier and its alteration in immune mediated neuropathies

Journal of neurology, neurosurgery, and psychiatry (Impact Factor: 5.58). 12/2012; 84(2). DOI: 10.1136/jnnp-2012-302312
Source: PubMed

ABSTRACT The blood-nerve barrier (BNB) is a dynamic and competent interface between the endoneurial microenvironment and the surrounding extracellular space or blood. It is localised at the innermost layer of the multilayered ensheathing perineurium and endoneurial microvessels, and is the key structure that controls the internal milieu of the peripheral nerve parenchyma. Since the endoneurial BNB is the point of entry for pathogenic T cells and various soluble factors, including cytokines, chemokines and immunoglobulins, understanding this structure is important to prevent and treat human immune mediated neuropathies such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes) syndrome and a subset of diabetic neuropathy. However, compared with the blood-brain barrier, only limited knowledge has been accumulated regarding the function, cell biology and clinical significance of the BNB. This review describes the basic structure and functions of the endoneurial BNB, provides an update of the biology of the cells comprising the BNB, and highlights the pathology and pathomechanisms of BNB breakdown in immune mediated neuropathies. The human immortalised cell lines of BNB origin established in our laboratory will facilitate the future development of BNB research. Potential therapeutic strategies for immune mediated neuropathies manipulating the BNB are also discussed.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Several high-quality publications were published in 2013 and some major trials studies were started. In Guillain-Barré syndrome, events included the launch of IGOS and a better understanding of diagnostic limits, the effect of influenza vaccination, and better care, but uncertainty remains about analgesics. A new mouse model was also described. In chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), diagnostic pitfalls can be recalled. Our knowledge of underlying pathophysiological processes has improved, and the value of monitoring with function and deficit scores has been demonstrated. IVIG can sometimes be effective longer than expected, but CIDP remains sensitive to corticosteroids, particularly with the long-term beneficial effects of megadose dexamethasone. The impact of fingolimod remains to be demonstrated in an ongoing trial. Advances concerning multifocal motor neuropathy, inflammatory plexopathy, and neuropathy with anti -MAG activity are discussed but treatments already recognized as effective should not be changed. Imaging of peripheral nerve progresses. Copyright © 2014 Elsevier Masson SAS. All rights reserved.
    Revue Neurologique 11/2014; DOI:10.1016/j.neurol.2014.05.011 · 0.60 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome is a rare cause of demyelinating neuropathy with upregulation of vascular endothelial growth factor (VEGF). This study aimed to elucidate axonal excitability properties and their relation to VEGF levels and nerve edema in POEMS neuropathy. Axonal excitability measurement and nerve ultrasound were performed in the median nerve of 33 patients with POEMS syndrome. Serum VEGF levels were measured by ELISA. Compared with normal subjects (n=87), POEMS patients showed longer strength-duration time constant, fanning-out of threshold electrotonus curves, and greater threshold changes in a hyperpolarizing current-threshold relationship. Nerve ultrasound showed significant enlargement in POEMS patients. Serum VEGF levels and the extent of nerve edema partly correlated with nerve conduction slowing, as well as persistent sodium currents and inward rectification. In POEMS syndrome, patterns of changes in excitability properties could suggest increased persistent sodium currents, and impaired potassium and inward rectifying channels. The findings were not consistent with depolarization due to nerve edema and compression ischemia. In addition to demyelination, nerve edema induced by upregulated VEGF, and upregulated inflammatory cytokines could modulate profiles of POEMS neuropathy. Copyright © 2015 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.
    Clinical neurophysiology: official journal of the International Federation of Clinical Neurophysiology 02/2015; DOI:10.1016/j.clinph.2015.01.018 · 2.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Previous therapeutic strategies for multiple sclerosis (MS) include the non-selective suppression of systemic immunity (immunosuppressive agents, such as glucocorticoids, mitoxantrone and azathioprine) and immunomodulation (type I interferons or intravenous immunoglobulin). The recent development of two pivotal drugs, fingolimod and natalizumab, has resulted in a third category of MS treatment, namely the sequestration of pathogenic T cells. Natalizumab, a humanized monoclonal antibody that binds to the α4-integrin molecule on the surface of circulating lymphocytes and thus blocks very late antigen-4/vascular cell adhesion molecule-1 interactions at the blood–brain barrier (BBB), is now widely accepted as a potent tool for treating relapsing–remitting MS. This drug is epoch-making, as it is the first agent to confirm the efficacy of merely inhibiting the transfer of T cells across the BBB in the treatment of MS; however, the risk of a potentially fatal central nervous system opportunistic infection, progressive multifocal leukoencephalopathy, should always be kept in mind. Because the onset of progressive multifocal leukoencephalopathy might be partly due to the almost total blockage of T cells, including those participating in immune surveillance, the development of novel therapies that selectively inhibit only the entrance of pathogenic T cells is now eagerly awaited. In addition to the blockade of mononuclear cell intrusion, restoring the integrity of the BBB might quickly terminate the process of local inflammation. In addition, manipulating the BBB to enhance the transfer of useful molecules, including a variety of growth factors, could facilitate axonal regeneration. Therefore, the BBB is a promising target of future therapeutic strategies in MS.
    12/2014; 5(s1). DOI:10.1111/cen3.12167